5:31 PM
 | 
Dec 09, 2009
 |  BC Extra  |  Company News

Cytokinetics, GSK end cancer deal

Cytokinetics Inc. (NASDAQ:CYTK) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) agreed to terminate a 2001 cancer deal, including returning rights to the biotech for GSK- 923295. GSK will complete an ongoing...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >